Alcresta Investment Reflects Omega Market Growth
This article was originally published in The Tan Sheet
Executive Summary
Alcresta is developing omega-3 and -6 fatty acid supplements that are more easily digested and absorbable. Founders Alexey Margolin and Robert Gallotto look to repeat the success they had in 2010 when they sold an earlier nutritionals start-up for $180 million.
You may also be interested in...
In Brief
FDA probes AeroShot energy canister; state cannot force pharmacists to provide Plan B; analysts boost Herbalife earnings estimates; consumers allege Gerber makes false probiotics claims; more news In Brief.
Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
On Q3 Earnings Call, Lilly Vows To Stay Its Current Course Despite Late-Stage Pipeline Setbacks
As analysts call for transformative M&A, executives talked up Lilly's modest diversification efforts, including its animal health business, Elanco, and strong Japanese sales.